Castrate resistant prostate cancer is a disease state which, counterintuitively, can be successfully treated with additional therapy directed at inhibition of androgen synthesis and/or interfering with the activity of the androgen receptor.
Novel androgen biosynthesis inhibitors and antiandrogens are now being tested in large phase 3 clinical trials to clarify their role in the treatment of men who have failed traditional medical castration, with or without currently available nonsteroidal antiandrogens. A renewed interest in studying parenteral delivery of estrogens may provide evidence to revisit the initial medical therapy for advancing prostate cancer.
Written by:
Schellhammer P. Are you the author?
Eastern Virginia Medical School, Virginia Beach, VA 23464, USA.
Reference: Urol Oncol. 2012 Jul;30(4 Suppl):S10-4.
doi: 10.1016/j.urolonc.2012.01.009
PubMed Abstract
PMID: 22795075
UroToday.com Prostate Cancer Section
